相关实验视频
Updated: Jul 18, 2026
07:07
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
BRAF突变预测了对MEK抑制的敏感性
David B Solit1, Levi A Garraway, Christine A Pratilas
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA.
Nature
|November 8, 2005
概括
与RAS突变瘤不同,BRAF突变瘤对MEK抑制剂具有很高的敏感性. 这一发现支持MEK抑制剂作为BRAF突变癌症的向治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症遗传学 癌症遗传学
背景情况:
- 在人类癌症中,RAS/RAF/MEK/ERK激酶通路经常被激活.
- 在RAS和RAF家族成员中的功能获取突变驱动了这种激活.
- 准这种途径是癌症治疗的关键策略.
研究的目的:
- 为了研究具有BRAF与RAS突变的瘤对MEK抑制的差异敏感性.
- 阐明BRAF突变细胞中MEK抑制剂敏感性背后的分子机制.
- 评估MEK抑制剂在基因定义的瘤亚型中的治疗潜力.
主要方法:
- 使用小分子MEK抑制剂.
- 进行了综合遗传和药理学分析.
- 在BRAF突变体,RAS突变体和野生类型细胞和异种移植中比较MEK抑制效应.
- 评估cyclin D1蛋白表达和细胞循环停止的变化 (G1).
主要成果:
- 与野生类型或RAS突变细胞相比,BRAF突变细胞对MEK抑制具有增强和选择性的敏感性.
- 这种敏感性独立于组织谱系,与循环素D1下调和G1停止相关.
- 药理上的MEK抑制导致了BRAF突变异种移植中瘤生长的完全废除.
- 拉斯突变瘤仅表现出部分抑制与MEK抑制.
结论:
- BRAF突变瘤对MEK通路活动具有极大的依赖性.
- MEK 抑制剂是 BRAF 突变瘤的合理和有效的治疗策略.
- 这项研究确定了一种基因定义的瘤亚型,该亚型容易受到针对性的MEK抑制.
更多相关视频
07:49Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
06:44Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells
Published on: March 1, 2024
相关概念视频
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...